DRUG · Mapped RxNorm record
Pegzilarginase
Normalized identity: pegzilarginaseView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
NCT03371979
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Pembrolizumab
Normalized identity: pembrolizumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedPegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Small-cell Lung Cancerunresolved
Interventions
PegzilarginaseDRUG · verified · RxNorm: pegzilarginase
PembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Aeglea Biotherapeuticslead sponsor
Merck Sharp & Dohme LLCcollaborator
Mapped research locations
HoustonTexas, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1PittsburghPennsylvania, United States1CincinnatiOhio, United States1TampaFlorida, United States1PortlandOregon, United States1AuroraColorado, United States1DenverColorado, United States1DetroitMichigan, United States1OmahaNebraska, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03371979 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.